WALTHAM,
Mass., Sept. 14, 2023 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology
company advancing a pipeline of antibody therapeutics with the
potential to transform the treatment of inflammatory bowel disease
("IBD"), today announced that management will participate in the
Stifel 2023 Immunology & Inflammation Virtual Summit.
Chief Operating Officer Cameron
Turtle, DPhil, will be speaking at a fireside chat amongst
leading public and private biotech companies in the Immunology and
Inflammation space on Wednesday, September
20, 2023 from 11:00 am to 11:45 am
Eastern Standard Time. Online streaming of the chat will be
available.
Participants can view the webcast through the following link:
https://wsw.com/webcast/stifel82/agle/2058441
About Aeglea BioTherapeutics
In June 2023, Aeglea completed the asset acquisition
of Spyre Therapeutics, Inc. and shifted its disease focus to IBD.
Aeglea is advancing a pipeline of antibody therapeutics with the
potential to transform the treatment of IBD. The approaches combine
novel antibody engineering, rational therapeutic combinations, and
precision immunology approaches to maximize efficacy, safety, and
convenience of treatments for IBD. The company's portfolio includes
potentially best-in-class antibodies targeting α4β7, TL1A, and
IL-23.
Forward-Looking Statements
Certain statements in the
fireside chat, other than purely historical information, may
constitute "forward-looking statements" within the meaning of the
federal securities laws, including for purposes of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995, concerning Aeglea and other matters. These
forward-looking statements include, but are not limited to, express
or implied statements relating to Aeglea's management team's
expectations, hopes, beliefs, intentions or strategies regarding
the future including, without limitation, Aeglea's business plans
and the anticipated benefits of the management changes. In
addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking
statements. The words "opportunity," "potential," "milestones,"
"pipeline," "can," "goal," "aim," "strategy," "target," "seek,"
"anticipate," "achieve," "believe," "contemplate," "continue,"
"could," "estimate," "expect," "intends," "may," "might," "plan,"
"possible," "predict," "project," "should," "will," "would" and
similar expressions (including the negatives of these terms or
variations of them) may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements are based on
current expectations and beliefs concerning future developments and
their potential effects. There can be no assurance that future
developments affecting Aeglea will be those that have been
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond Aeglea's control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited those uncertainties and factors described under
the heading "Risk Factors" and "Note about Forward-Looking
Statements" in Aeglea's most recent Quarterly Report on Form 10-Q
filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors included in other
filings by Aeglea from time to time. Should one or more of these
risks or uncertainties materialize, or should any of Aeglea's
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Nothing in the fireside chat should be regarded as a representation
by any person that the forward-looking statements set forth therein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements in the fireside chat,
which speak only as of the date they are made and are qualified in
their entirety by reference to the cautionary statements herein.
Aeglea does not undertake or accept any duty to release publicly
any updates or revisions to any forward-looking statements. This
press release does not purport to summarize all of the conditions,
risks and other attributes of an investment in Aeglea.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-upcoming-september-conference-301928504.html
SOURCE Aeglea